Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
Axel Le Cesne(Institut Gustave Roussy), Ole S. Nielsen(Science Museums), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Ian Judson(Erasmus Hospital), Sylvie Bonvalot(Dana-Farber Cancer Institute), A. van Oosterom(European Organisation for Research and Treatment of Cancer), Paul Lorigan(Manchester Academic Health Science Centre), José Jimeno(European Organisation for Research and Treatment of Cancer), Isabelle Ray‐Coquard(European Organisation for Research and Treatment of Cancer), M. van Glabbeke(Institut Jules Bordet), Jaap Verweij(Deutz (Germany)), F. Collin(European Organisation for Research and Treatment of Cancer), John Radford(Manchester Academic Health Science Centre), Sjoerd Rodenhuis(The Netherlands Cancer Institute), ED Di Paola(European Organisation for Research and Treatment of Cancer)
Cited by 421
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k